chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Cough, Dyspnoea, Headache, Migraine
Clinical narrative: Cough/second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Chest pain/ second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Rib pain/second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Difficulty breathing / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Nausea / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Migraines / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; First day of second dose I was fine just a mild headache; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm right on 10May2021 at 12:45 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the arm right on 19Apr2021 at 13:00 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 11May2021, first day of second dose the patient was fine just a mild headache. But after the second day on 12May2021, the patient felt like she had been getting worse had a cough, chest pain, rib pain, difficulty breathing, nausea, and migraines. The patient had been taking cough medicine but was not working. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of cough which include treatment with medicine unspecified. The clinical outcome of the events just a mild headache, had a cough, chest pain, rib pain, difficulty breathing, nausea, and migraines were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal chest pain, Nausea
Clinical narrative: Cough/second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Chest pain/ second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Rib pain/second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Difficulty breathing / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Nausea / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; Migraines / second day I feel like I have been getting worse I have a cough chest pain rib pain and difficulty breathing nausea and migraines; First day of second dose I was fine just a mild headache; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm right on 10May2021 at 12:45 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the arm right on 19Apr2021 at 13:00 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 11May2021, first day of second dose the patient was fine just a mild headache. But after the second day on 12May2021, the patient felt like she had been getting worse had a cough, chest pain, rib pain, difficulty breathing, nausea, and migraines. The patient had been taking cough medicine but was not working. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of cough which include treatment with medicine unspecified. The clinical outcome of the events just a mild headache, had a cough, chest pain, rib pain, difficulty breathing, nausea, and migraines were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Strong headache starting around 6pm (approximately 3 hours after shot); Sore arm around injection site starting about an hour after shot; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 13-year-old, non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the right arm on 13May2021 at 15:00 (at the age of 13-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was reported as none. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any medication within two weeks of the COVID-19 vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 13May2021 at 16:00, the patient experienced sore arm around injection site which started about an hour after the shot which continued through the next day. On 13May2021 around 18:00, the patient experienced a strong headache (approximately 3 hours after shot). On 13May2021, in the evening of the vaccination day and the day after the shot, the patient experienced fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events sore arm around injection site and fatigue. Therapeutic measures were taken as a result of the event strong headache which included treatment with over the counter (OTC) TYLENOL and headache went away in a few hours. The clinical outcome of events sore arm around injection site, strong headache and fatigue was resolved on an unknown date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chest discomfort, Chest pain
Clinical narrative: got a pain started out feeling like mid back pain, and became more of a chest pain. It was an aching and stabbing pain heavy to the chest.; got a pain started out feeling like mid back pain, and became more of a chest pain. It was an aching and stabbing pain heavy to the chest.; got a pain started out feeling like mid back pain, and became more of a chest pain. It was an aching and stabbing pain heavy to the chest.; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm right on 04May2021 at 08:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis, asthma, depression, anxiety, thyroid disorder, scoliosis and penicillin allergy. Concomitant medications included levothyroxine sodium (SYNTHROID), bupropion hydrochloride (WELLBUTRIN), methylphenidate hydrochloride (RITALIN), solifenacin succinate (VESICARE) and tiotropium bromide monohydrate (SPIRIVA); all from unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the arm right on 13Apr2021 at 08:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On 05May2021 at 14:00, the following day after the shot, about 30 hours after shot, the patient started out feeling like mid back pain and became more of a chest pain. The patient fell asleep for two hours and was woken up by the chest pain worsening. Lasted about four hours. It was an aching and stabbing pain heavy to the chest. Therapeutic measures were taken as a result of the events and included treatment with 325 ASPIRIN. The clinical outcome of the events got a pain started out feeling like mid back pain, became more of a chest pain and aching and stabbing pain heavy to the chest was recovered on 05May2021.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: Period was delayed by 5 days (33 days in the cycle); This is a spontaneous report from a contactable consumer, the patient. This is the first of two reports. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; solution for injection, Lot Number: EW0158), via an unspecified route of administration in the left arm on 07Apr2021 at 15:30 (at the age of 38-years-old), as a single dose for COVID-19 immunization. The patient had no medical history. The patient did not have any allergies to medications, food or other products. Concomitant medications included multivitamins and cod-liver oil. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On unknown date, the patient experienced period was delayed by 5 days (33 days in the cycle) after the first dose. The patient mentioned that regular cycle length was 26 days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event period was delayed by 5 days (33 days in the cycle) was unknown at the time of reporting.   No follow-up attempts were needed. No further information was expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Moderate to severe joint pain, particularly in hands, but also hips, elbows; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 12:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included triglycerides high. The patient did not have any allergies to medications, food, or other products Concomitant medications included omega-3-acid ethyl ester (LOVAZA), BCP (UNKNOWN MANUFACTURER), Ipatroprium NS (UNKNOWN MANUFACTURER), mefenamic acid (ADVIL), curcuma longa (TURMERIC), colecalciferol, retinol (VITA) all from unknown dates and for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 11Mar2021 at 12:00 (at the age of 56-year-old), as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 the patient experienced moderate to severe joint pain, particularly in hands, but also hips, elbows. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event severe joint pain, particularly in hands, but also hips, elbows was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Disturbance in attention, Fatigue, Hot flush, Lethargy
Clinical narrative: Had difficulty focusing and concentrating; had shaking in my hands; chills; Hot flashes; eventually leading to muscle aches; swelling of my left arm.; swelling of left leg; heaviness in my left arm; lethargy; easily fatigued; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 13May2021 at 10:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no allergies to medications, food, or other products. The patient did not receive any other medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 22Apr2021 at 10:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13May2021 at 12:45, within two hours of receiving the second dose, the patient experienced difficulty in focusing and concentrating, had shaking in hands that could not be stopped, chills, hot flashes which eventually led to muscle aches on the left side of the body, swelling of left arm and left leg, heaviness in left arm and lethargy/easily fatigued. The worst pain was between 23:00 and 06:00 of next day, which was about 12 hours after the shot. The patient also reported that he did not have symptoms after the first dose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events difficulty in focusing and concentrating, shaking in hands, chills, hot flashes, muscle aches on the left side of the body, swelling of left arm and left leg, heaviness in left arm and lethargy/easily fatigued were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Limb discomfort, Myalgia, Peripheral swelling, Tremor
Clinical narrative: Had difficulty focusing and concentrating; had shaking in my hands; chills; Hot flashes; eventually leading to muscle aches; swelling of my left arm.; swelling of left leg; heaviness in my left arm; lethargy; easily fatigued; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 13May2021 at 10:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no allergies to medications, food, or other products. The patient did not receive any other medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 22Apr2021 at 10:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13May2021 at 12:45, within two hours of receiving the second dose, the patient experienced difficulty in focusing and concentrating, had shaking in hands that could not be stopped, chills, hot flashes which eventually led to muscle aches on the left side of the body, swelling of left arm and left leg, heaviness in left arm and lethargy/easily fatigued. The worst pain was between 23:00 and 06:00 of next day, which was about 12 hours after the shot. The patient also reported that he did not have symptoms after the first dose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events difficulty in focusing and concentrating, shaking in hands, chills, hot flashes, muscle aches on the left side of the body, swelling of left arm and left leg, heaviness in left arm and lethargy/easily fatigued were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Rash pruritic, Vaccination site pruritus, Vaccination site rash
Clinical narrative: Itchy rash at site of injection; Itchy rash at site of injection; itchy rash on right lower back, right thigh and behind left knee and back of left thigh; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 65-years-old), as a single dose for COVID-19 immunisation. Medical history included inflammatory bowel disease and known allergies to bananas and raspberries. The patient received unspecified medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 11Mar2021 (at the age of 65-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021, the patient experienced itchy rash at site of injection and on right lower back, right thigh and behind left knee and back of left thigh. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event itchy rash at site of injection and on right lower back, right thigh and behind left knee and back of left thigh was not recovered at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Fatigue, Headache, Panic attack
Clinical narrative: I have had severely worsened anxiety; I have had severely worsened anxiety, new panic attacks Ive never had before,; Daily headaches; Waves of extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 18Mar2021 at 18:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety and depression. The patient did not have any allergies to medications, food, or other products. Concomitant medications included oral birth control nos (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 18Mar2021, the patient experienced severely worsened anxiety, new panic attacks she had never had before, daily headaches, and waves of extreme fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the reported events. The clinical outcome of the events anxiety, panic attacks, headaches and fatigue was not resolved/ongoing at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 09Apr2021 at 18:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Feeling hot, Injection site pain
Clinical narrative: Muscle Pain at injection site; Joint pains; feeling of heat around  body; fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 14May2021 at 13:00(at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma and allergic to gluten. Concomitant medications included quetiapine fumarate (SEROQUEL) 200mg from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 22:00, the patient experienced muscle pain at injection site, joint pains, feeling of heat around body and fatigue. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events muscle pain at injection site, joint pains, feeling of heat around body and fatigue was not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Nasopharyngitis, Nausea, Pain
Clinical narrative: Pain; acheness; light headed; weak; nausea; severe pain in arm; cold; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14May2021 at 15:00 (at the age of 34-year-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN), amfetamine aspartate; amfetamine sulfate; dexamfetamine saccharate; dexamfetamine sulfate (ADDERALL) and folic acid (MANUFACTURER UNKNOWN) all from unknown date for unspecified indications. The patient did not have a history of allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 17:45 the patient experienced pain, achiness, light headed, weak, nausea, severe pain in arm and cold. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcomes of the events pain, achiness, light headed, weak, nausea, severe pain in arm and cold was not recovered at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Pain; acheness; light headed; weak; nausea; severe pain in arm; cold; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14May2021 at 15:00 (at the age of 34-year-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN), amfetamine aspartate; amfetamine sulfate; dexamfetamine saccharate; dexamfetamine sulfate (ADDERALL) and folic acid (MANUFACTURER UNKNOWN) all from unknown date for unspecified indications. The patient did not have a history of allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 17:45 the patient experienced pain, achiness, light headed, weak, nausea, severe pain in arm and cold. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcomes of the events pain, achiness, light headed, weak, nausea, severe pain in arm and cold was not recovered at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: developed a fever; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0168) via an unspecified route of administration in the left arm on 14May2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no allergies to medications, food, or other products. Concomitant medications included ibuprofen (ADVIL), taken from an unknown date for an unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 19:30, about 10 hours after vaccination, the patient developed a fever that got up to over 104 degrees. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fever was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Ear pain, Neck pain, Visual impairment
Clinical narrative: Light headed; vision changes; Neck pain; Ear pain; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15May2021 at 11:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The medical history of the patient included chronic pain, depression and anxiety. The patient received other medications in two weeks, and was unspecified. The patient previously took Neosporin and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 17Apr2021 at 11:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 12:45, the patient experienced light headed and vision changes, neck pain and ear pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events light headed, vision changes, neck pain and ear pain were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 15.0
Sex: M
Vaccine: COVID19
Symptoms: Adverse event, SARS-CoV-2 test
Clinical narrative: idk; This is a spontaneous report from a contactable consumer, the patient. A 15-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 15May2021 at 15:30 (at the age of 15-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any medications within two weeks of the COVID-19 vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 15May2021, the patient reported that he experienced "idk". On 15May2021, the patient underwent a nasal swab test, the results of which were not known. It was unknown whether any therapeutic measures were taken as a result of the event. The clinical outcome of the event "idk" was unknown at the time of this report.   No follow up attempts are needed; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Hangover, Vertigo
Clinical narrative: Vertigo / hangover-like symptoms; hangover-like symptoms; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 15:00(at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 14:00(at the age of 30-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 14May2021 at 12:00 after 3-4 days of second dose, the patient experienced vertigo / hangover-like symptoms. The symptoms was lasted at least 24 hours. The patient reported that he had no medical history of vertigo or onset dizziness prior to vaccination. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event vertigo and hangover-like symptoms was resolved on 15May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Body temperature, Dry mouth, Heart rate
Clinical narrative: Racing pulse (150 bpm); Fever (99.7 F); Body aches; Pain at site of surgery within past years; Dry mouth; Loss of taste; Loss of smell; Soreness at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167), via an unspecified route of administration in the left arm on 14May2021 at 10:15 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. Medical history included major depression, tenosynovial giant cell tumor and soft tissue inflammation of the back and neck. The patient had known allergies to penicillin, zolpidem tartrate (AMBIEN), walnuts and pecans. Concomitant medications included sertraline hydrochloride (ZOLOFT), cyclobenzaprine hydrochloride (FLEXERIL), ibuprofen (MANUFACTURER UNKNOWN) and fluticasone propionate (FLONASE); all from unknown dates for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729), via an unspecified route of administration in the left arm on 20Apr2021 at 12:00, as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 00:00, the patient experienced racing pulse (150 bpm), fever (99.7 F), body aches, pain at site of surgery within past years, dry mouth, loss of taste, loss of smell and soreness at injection site. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 15May2021 at 00:00, the patient underwent lab test and procedures which included body temperature and the result was 99.7 F and for pulse rate the result was 150 bpm. The clinical outcome of the events racing pulse (150 bpm), fever (99.7 F), body aches, pain at site of surgery within past years, dry mouth, loss of taste, loss of smell and soreness at injection site were resolving at the time of reporting.    No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Racing pulse (150 bpm); Fever (99.7 F); Body aches; Pain at site of surgery within past years; Dry mouth; Loss of taste; Loss of smell; Soreness at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167), via an unspecified route of administration in the left arm on 14May2021 at 10:15 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. Medical history included major depression, tenosynovial giant cell tumor and soft tissue inflammation of the back and neck. The patient had known allergies to penicillin, zolpidem tartrate (AMBIEN), walnuts and pecans. Concomitant medications included sertraline hydrochloride (ZOLOFT), cyclobenzaprine hydrochloride (FLEXERIL), ibuprofen (MANUFACTURER UNKNOWN) and fluticasone propionate (FLONASE); all from unknown dates for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729), via an unspecified route of administration in the left arm on 20Apr2021 at 12:00, as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 00:00, the patient experienced racing pulse (150 bpm), fever (99.7 F), body aches, pain at site of surgery within past years, dry mouth, loss of taste, loss of smell and soreness at injection site. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 15May2021 at 00:00, the patient underwent lab test and procedures which included body temperature and the result was 99.7 F and for pulse rate the result was 150 bpm. The clinical outcome of the events racing pulse (150 bpm), fever (99.7 F), body aches, pain at site of surgery within past years, dry mouth, loss of taste, loss of smell and soreness at injection site were resolving at the time of reporting.    No follow-up attempts are possible. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus, Rash, Swelling
Clinical narrative: rashes like hives on body.; Severe itching; swelling; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 29Apr2021 at 15:00 (at the age of 35-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any other medications within two weeks prior to the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05May2021 at 13:00, the patient developed rashes like hives on body, severe itching and swelling. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with tropical cream. The clinical outcome of the events rashes like hives on body, severe itching and swelling was not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Increasing daily dizziness over the course of first and second week.  Third week in and  less frequent and much more mild dizziness.; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 23Apr2021 at 16:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient did not have any other medical history. The patient had no known allergies to medications, food, or other products. Other medication within two weeks of vaccination was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 14:00, the patient experienced increasing daily dizziness over the course of first and second week. Third week in and less frequent and much more mild dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the event increasing daily dizziness over the course of first and second week, third week in and less frequent and much more mild dizziness was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Migraine, SARS-CoV-2 test
Clinical narrative: headache; migraine; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) in the left arm on 24Mar2021 at 10:00 (at the age of 28-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included duloxetine hydrochloride (CYMBALTA) for unspecified indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 at 10:00 (at the age of 28-years-old), as a single dose for COVID-19 immunisation. On 24Mar2021 at 13:00, the patient experienced headache and migraine. The patient had been having continuous daily headaches and sometimes so bad as migraines ever since receiving the vaccine. The patient underwent lab tests and procedures which included rapid testing for COVID-19 on 15May2021 and the result was negative. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with sumatriptan. The clinical outcome for the events continuous daily headaches and sometimes so bad as migraines were not recovered at the time of reporting.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Feeling cold, Feeling hot, Headache
Clinical narrative: Nausea; General Body pain; Vomiting; Muscle pain; fatigue; Headcahe; Joint pain; was freezing; then burning up; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew0175) via an unspecified route of administration in the left arm on 14May2021 at 11:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis. The patient had no known allergies. Concomitant medications included birth control daily (UNSPECIFIED) and hydroxyzine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0153 ) via an unspecified route of administration in the left arm on 23Apr2021 at 11:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 the patient felt fine until about 12 hours after the second vaccine. The patient woke up at 00:30 and experienced nausea and pain all over her body, vomited for the following 12 hours and could not keep down food or liquids, no fever but she had freezing and then burning up. 29 hours since the vaccine, the patient felt moderately joint pain, muscle pain especially in the back of her neck, fatigue, nausea and severe headache. The patient did not receive any treatment for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events general body pain, nausea, vomiting, joint pain, freezing, burning up, muscle pain, fatigue and headache was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pain, Vomiting
Clinical narrative: Nausea; General Body pain; Vomiting; Muscle pain; fatigue; Headcahe; Joint pain; was freezing; then burning up; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew0175) via an unspecified route of administration in the left arm on 14May2021 at 11:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis. The patient had no known allergies. Concomitant medications included birth control daily (UNSPECIFIED) and hydroxyzine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0153 ) via an unspecified route of administration in the left arm on 23Apr2021 at 11:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 the patient felt fine until about 12 hours after the second vaccine. The patient woke up at 00:30 and experienced nausea and pain all over her body, vomited for the following 12 hours and could not keep down food or liquids, no fever but she had freezing and then burning up. 29 hours since the vaccine, the patient felt moderately joint pain, muscle pain especially in the back of her neck, fatigue, nausea and severe headache. The patient did not receive any treatment for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events general body pain, nausea, vomiting, joint pain, freezing, burning up, muscle pain, fatigue and headache was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.